Stephen V Liu, MD on Twitter: "RR 23% overall. With q2w dosing, RR 28%. mDOR 8.7m. In non-squamous, RR 18% (q2w RR 31%, q3w RR 6%). In squamous, RR 43% (all in
Darbepoetin treatment algorithm in anemia of chronic renal failure with Hb < 11 g/dl
Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study - ACR Meeting Abstracts
Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials | Scientific Reports
Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial | BMC Cancer
Patient disposition. QW = once weekly, Q2W = once every 2 weeks, Q3W =... | Download Scientific Diagram
Study design. IV intravenous, MTD maximum tolerated dose, Q2W once... | Download Scientific Diagram
Overview of selected cetuximab q2w dosing studies in which KRAS... | Download Table
Dosing & Administration - IMFINZI® (durvalumab)
Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study | International Journal of Dermatology and Venereology
Mean plasma concentration vs time curves for andecaliximab Q2W and QW.... | Download Scientific Diagram
Cancers | Free Full-Text | Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label,
GAIN-2 - GBG 68
g66721mmi001.jpg
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications - Scott M. Wasserman, Marc S. Sabatine, Michael J. Koren, Robert P. Giugliano, Jason C. Legg, Maurice
GAIN-2 - GBG 68
Study design. Q2W, 80 mg ixekizumab every 2 weeks; Q4W, 80 mg... | Download Scientific Diagram
Overview of selected cetuximab q2w dosing studies in which KRAS... | Download Table
Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective - ScienceDirect
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial - ScienceDirect
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial - ScienceDirect
Flexible dosing options for mNSCLC | TECENTRIQ® (atezolizumab)
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 m
Dupixent II-27 - EPAR
